Contact us.

Looking for a Serosep address or contact information? Visit our contact page.

info@serosep.com

+353 61 358190


    /Solutions /Molecular Solutions /PathoNostics B.V.

    PathoNostics B.V.

    About PathoNostics B.V.

    PathoNostics was founded in 2011 in Maastricht, The Netherlands and became an important player in the fungal diagnostic field. PathoNostics is focussing on the development and commercialization of real-time PCR kits for the diagnosis of superficial and invasive fungal infections. PathoNostics currently has four products on the market: AsperGenius®, DermaGenius®, PneumoGenius® and MucorGenius®.
    ‍
    PCR kits from PathoNostics enable a rapid and accurate diagnosis, leading to timely initiation of targeted therapy. The proprietary technology platform uses real-time PCR and melting curve analysis to detect and differentiate pathogens and identify resistance markers.

    Product's from PathoNostics B.V.

    Molecular PathoNostics B.V.
    AsperGenius®
    Invasive pulmonary aspergillosis (IPA) is the most frequent invasive mold infection in immunocompromised patients and is mainly caused by Aspergillus fumigatus (A. fumigatus).
    Learn More
    Molecular PathoNostics B.V.
    DermaGenius®
    Dermatophytes represent the most numerous and widespread group of all mycoses and have the capacity to invade keratinized tissue of humans and animals to facilitate infections that are generally restricted to the corneocytes of the skin, hair and nails. Dermatophytes are classified in three genera: Epidermophyton, Microsporum and Trichophyton.
    Learn More
    Molecular PathoNostics B.V.
    MucorGenius®
    Mucormycosis is a rare invasive fungal infection with exceedingly high mortality and few therapeutic options. The disease is caused by Mucorales, which is a large group of species within the order of zygomycetes.
    Learn More
    Molecular PathoNostics B.V.
    PneumoGenius®
    Pneumocystis pneumonia, a (major) opportunistic infection in immunocompromised patients, is caused by the fungus Pneumocystis jirovecii (P. jirovecii). The incidence of Pneumocystis pneumonia, which increased dramatically with the advent of the HIV/AIDS pandemic, has decreased in the industrialized world owing to the widespread use of sulfa drug prophylaxis and the introduction of highly active antiretroviral therapy (HAART). However, P. jirovecii remains an important cause of morbidity and mortality in HIV/AIDS patients, as well as in non-HIV immunocompromised patients, in whom its diagnosis is difficult.
    Learn More